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ILLUSTRATIVE CASE
A 34-year-old woman comes to your offi ce 
and asks to be taken off the paroxetine 
you prescribed for her 4 months ago. The 
medication is working well; her depression 
has been in remission for at least 12 
weeks. But she no longer enjoys sex. She 
used to have a healthy libido and satisfying 
arousal and orgasm, but since starting the 
antidepressant, her sexual interest and 
pleasure have been low. 
Although she’s afraid of sinking back 
into a depression without the medication, 
she’s willing to take the risk. If she were 
your patient, what alternatives would you 
suggest? 
Sexual dysfunction affects an es-timated 30% to 50% of patients on selective and nonselective SRIs, 
and some studies report rates as high as 
70% to 80%.2 Many patients stop taking 
these antidepressants prematurely, often 
because of sexual side effects.3,4 
Phosphodiesterase type 5 (PDE-5) in-
hibitors are well established as an effec-
tive treatment for erectile dysfunction,5 
and randomized controlled trials (RCTs) 
have shown sildenafi l to be effective in 
treating male SRI-induced sexual impair-
ment.6,7 For women, there has been no 
parallel evidence-based treatment. 
❚  Limited options, 
with little support 
Typically, women who reported antide-
pressant-associated sexual disturbances 
have been offered options for which there 
was only weak evidence—dose changes 
or augmentation with another agent, 
Tell women for whom you 
prescribe selective and non-
selective serotonin reuptake 
inhibitors (SRIs) to let you 
know if they develop sexual 
dysfunction. Offer sildenafi l 
(50 mg with the option to 
increase to 100 mg) to pre-
menopausal women on stable, 
effective doses of SRIs who 
experience this common—and 
treatable—side effect.1
Strength of recommendation 
B:  One high-quality RCT that confi rms smaller, open-label 
studies
Nurnberg HG, Hensley PL, Heiman JR, Croft HA, 
Debattista C, Paine S. Sildenafi l treatment of 
women with antidepressant-associated sexual 
dysfunction: a randomized controlled trial. JAMA. 
2008;300:395-404. 
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Sildenafi l boosted 
overall sexual 
function in women 
on SRIs, but had 
the greatest 
impact on 
orgasmic function
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switching to another antidepressant, or 
taking occasional drug holidays. A 2004 
Cochrane review found that there were 
no RCTs involving dose changes or drug 
holidays.8 Among studies of the effi ca-
cy of switching to a different drug, ne-
fazodone was the only agent whose use 
was supported by a double-blind RCT.9 
Augmentation trials of a wide range of 
medications and supplements—includ-
ing amantadine, bupropion, buspirone, 
granisetron, mirtazapine, olanzapine, 
ephedrine, ginkgo biloba, and yohim-
bine—yielded mixed results. Indeed, the 
research found that some were no better 
than placebo. 
PDE-5 inhibitors for women?
Inconclusive studies to date
Female sexual dysfunction is generally 
divided into 4 domains: disorders of de-
sire, arousal, orgasm, or pain.  Decreased 
desire and delayed or absent orgasm are 
the most common sexual side effects of 
SRI antidepressants in women.10 Several 
studies of PDE-5 inhibitors in this patient 
population have had positive results,11-15 
so there has been good reason to think 
that they might help this subset of wom-
en. However, all the studies were small 
and nonblinded, and therefore inconclu-
sive—until now.
STUDY SUMMARY 
❚  Finally, a well-done RCT
provides some answers 
Investigators enrolled 98 premenopaus-
al women from 7 US research centers 
in a double-blind randomized trial. To 
qualify, participants had to be diagnosed 
with major depression in remission, be 
taking a selective or nonselective SRI for 
>8 weeks, and be on a stable dose for 
>4 weeks. They also had to meet Diag-
nostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) criteria 
for substance-induced sexual dysfunc-
tion lasting >4 weeks, but have no his-
tory of sexual impairment independent 
of antidepressants. Finally, participants 
had to engage in some form of regular 
sexual activity—intercourse, oral sex, 
and masturbation all qualifi ed—at least 
twice a month, and be willing to con-
tinue efforts to have sex at least once a 
week during the study. Women with oth-
er medical, psychiatric, or sexual prob-
lems were excluded, as were those who 
were pregnant, breastfeeding, or able to 
become pregnant and not using reliable 
contraception.
Participants were randomized to 
receive 50 mg of sildenafi l (n=49) or a 
matching placebo tablet (n=49), which 
they were instructed to take 1 to 2 hours 
before sexual activity. The dose could be 
adjusted to 2 tablets (100 mg sildenafi l) 
based on investigator assessment of the 
patient’s response to the initial dose. Par-
ticipants and all study personnel were 
blinded to group assignment.
The primary outcome was change 
from baseline to end-point in the Clini-
cal Global Impression Scale, a clinician-
rated scale based on review of patient 
symptoms that was adapted to evaluate 
sexual function. Secondary outcomes 
were changes in 3 other sexual function 
scales, the Hamilton Rating Scale for De-
pression, and measured hormone levels.
Investigators followed the women 
for 8 weeks, measuring outcomes at 2, 4, 
and 8 weeks.
Sildenaﬁ l is better than placebo 
Using an intention-to-treat analysis 
with the last measurement (2, 4, or 
8 weeks) as the end-point, both the 
treatment and placebo groups experi-
enced improvement in sexual function. 
The sildenafi l group improved more 
than the placebo group. On the Clinical 
Global Impression Scale (1 to 7, with 
higher scores indicating worse sexual 
function), sildenafi l users went from a 
mean of 4.8 to 2.8, while placebo us-
ers went from a mean of 4.7 to 3.6. The 
difference in mean change from base-
line was 0.8 (95% confi dence interval 
[CI] 0.6-1.0; P=.001). Using a more 
conservative analysis in which partici-
pants who did not return for the 8-week 
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
Some researchers 
argue that female 
sexual dysfunction 
has been deﬁ ned 
by drug companies 
seeking to create 
new markets for 
their products
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follow-up visit were assumed to have 
returned to baseline, the difference in 
mean change from baseline was smaller 
(0.6, 95% CI, 0.3-0.8; P=0.03) but still 
statistically signifi cant. 
Orgasmic function shows 
signiﬁ cant improvement 
The sexual function scales used as sec-
ondary outcomes provided more detail 
about which types of sexual dysfunction 
benefi ted from sildenafi l. On all 3 scales, 
orgasmic function signifi cantly favored 
sildenafi l over placebo. In the domains of 
desire, arousal, and pain disorders, small 
to moderate improvements were seen in 
both groups, with no statistically signifi -
cant differences. One potential confound-
er—a difference in the course of partici-
pants’ underlying depression— was ruled 
out because depression scale results re-
mained unchanged from baseline to end-
point in both groups. 
Baseline levels of cortisone, estradiol, 
follicle-stimulating hormone, leuteinizing 
hormone, progesterone, prolactin, sex 
hormone-binding globulin, testosterone, 
thyroid-stimulating hormone, and thyrox-
ine, were normal, with no differences be-
tween the sildenafi l and placebo groups. 
WHAT’S NEW
❚  Women have an 
evidence-based option 
Like their male counterparts, we can now 
offer women whose depression is effec-
tively treated by SRI antidepressants—
and  who are motivated to stay sexually 
active despite medication-associated side 
effects—an effective pharmacotherapeu-
tic treatment.
CAVEATS 
❚  Side effects and study 
funding are worth noting
Side effects. Signifi cantly more par-
ticipants in the sildenafi l group vs the 
placebo group experienced the fol-
lowing side effects: headache (43% 
vs 27%), visual disturbance (14% vs 
2%), dyspepsia (12% vs 0%), fl ushing 
(24% vs 0%), nasal congestion (37% 
vs 6%), and palpitations (8% vs 2%). 
Nausea was the only side effect that was 
more common in the placebo group, re-
ported by only 2% of those in the in-
tervention group but 16% of those on 
placebo. 
No serious adverse events occurred, 
however, and the medication appears to 
have been well tolerated overall, despite 
relatively high rates of side effects. Par-
ticipants in the intervention group used 
an average of 5 doses of sildenafi l per 2-
week interval, the same number as those 
in the placebo group. 
Small treatment effect. The differ-
ence in response between sildenafi l and 
placebo was not large: 0.8 points on a 7-
point scale. But this difference is likely a 
clinically meaningful effect to the women 
with this problem.
Drug company funding. Pfi zer, the 
maker of Viagra, funded this study 
through an investigator-initiated grant. 
Some researchers argue that female 
sexual dysfunction has been defi ned, 
or even invented, by drug companies 
seeking to create new markets for their 
products.16 This concern, coupled with 
the fact that this is the only double-blind 
randomized trial to show that sildenafi l 
benefi ts women with antidepressant-
associated sexual impairment, raises the 
question of whether this fi nding will be 
replicated in future trials. 
We were reassured by the authors’ 
statement that Pfi zer had no role in the 
study design, implementation, analy-
sis, or manuscript preparation. And we 
know from clinical practice that wom-
en do suffer from SRI-induced sexual 
side effects, and sometimes stop taking 
much-needed antidepressants because 
the medication interferes with their abil-
ity to have a satisfying sex life. We be-
lieve this study was well done and offers 
a promising new therapy that deserves 
consideration. We hope that additional 
trials will follow and that investigators 
and journals will not hesitate to publish 
negative results.
When you 
prescribe SRI 
antidepressants 
to women, let 
them know that 
sexual side effects 
are common−and 
treatable
C O N T I N U E D
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❚  Not for all women 
with sexual dysfunction
It’s a safe bet that these fi ndings will be 
used to market sildenafi l to women.  It 
is therefore important for physicians 
and patients to keep in mind that this 
trial focused on a well-defi ned subset of 
women with sexual dysfunction: those 
on a stable dose of an SRI, with depres-
sion in remission, who were otherwise 
healthy and not pregnant, breastfeed-
ing, or planning pregnancy, and who 
were motivated to be sexually active. 
Although this study does support the 
use of sildenafi l for women in this sub-
set, it does not support the use of PDE-5 
inhibitors such as sildenafi l for all wom-
en with sexual diffi culties. 
CHALLENGES TO IMPLEMENTATION
❚ You have to ask!
Studies have repeatedly found that many 
women who experience sexual problems 
do not broach the subject with their 
doctors.17 So don’t wait for your female 
patients to bring it up. Sexual side ef-
fects are common enough with SRI an-
tidepressants that all prescribers should 
mention the possibility in advance. Tell 
patients to let you know if they develop 
medication-related sexual dysfunction, 
and reassure them that there are treat-
ments that can help. ■
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To fi nd out  
whether a 
female patient 
is experiencing 
antidepressant-
associated sexual 
dysfunction, you 
have to ask
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